(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
The Cancer and Blood Diseases Institute is home to specialists with a wide variety of backgrounds and areas of focus. As a team, this diversity makes us better prepared to care for your child’s unique needs. Learn more about our faculty and staff.
Stella M. Davies, MBBS, PhD, MRCP Director, Bone Marrow Transplantation and Immune Deficiency 513-636-1371 firstname.lastname@example.org
Director, Bone Marrow Transplantation and Immune Deficiency
Jacob G. Schmidlapp Endowed Chair
Co-Executive Director, Cancer and Blood Diseases Institute
Professor, UC Department of Pediatrics
MBBS: University of Newcastle-Upon-Tyne, England, 1981.
Clinical and Fellowship Training: The Royal Victoria Infirmary, Newcastle General Hospital and Great Ormond St. Hospital, 1981 to 1985.
PhD: University of Newcastle-Upon-Tyne, England, 1989.
Pediatric Fellowship: University of Minnesota, Minneapolis, MN, 1989 to 1993.
Mehta PA, Harris RE, Davies SM, Kim MO, Mueller R, Lampkin B, Mo J, Myers K, Smolarek TA. Numerical chromosomal changes and risk of development of myelodysplastic syndrome -- acute myeloid leukemia in patients with Fanconi anemia. Cancer Genet Cytogenet. 2010 Dec;203(2):180-6.
Jodele S, Bleesing JJ, Mehta PA, Filipovich AH, Laskin BL, Goebel J, Pinkard SL, Davies SM. Successful early intervention for hyperacute transplant-associated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation. Pediatr Transplant. 2010 Nov 5.
Marsh RA, Vaughn G, Kim MO, Li D, Jodele S, Joshi S, Mehta PA, Davies SM, Jordan MB, Bleesing JJ, Filipovich AH. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 2010 Dec 23;116(26):5824-31.Laskin BL, Goebel J, Davies SM, Khoury JC, Bleesing JJ, Mehta PA, Filipovich AH, Paff ZN, Lawrence JM, Yin HJ, Pinkard SL, Jodele S. Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplant. 2010 Aug 9.Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley IT, Meshinchi S, Bhatla D, Radloff G, Davies SM. MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010 Aug;55(2):248-53.
Mehta PA, Vinks AA, Filipovich A, Bleesing J, Jodele S, Jordan MB, Marsh R, Tarin R, Edwards S, Fearing D, Lawrence J, Davies SM. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant. 2010 Oct;16(10):1458-62.
Sakagami T, Beck D, Uchida K, Suzuki T, Carey BC, Nakata K, Keller G, Wood RE, Wert SE, Ikegami M, Whitsett JA, Luisetti M, Davies S, Krischer JP, Brody A, Ryckman F, Trapnell BC. Patient-derived granulocyte / macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates. Am J Respir Crit Care Med. 2010 Jul 1;182(1):49-61.
Wang D, Zhang W, Kalfa TA, Grabowski G, Davies S, Malik P, Pan D. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19958-63.
Davies SM, Wang D, Wang T, Arora M, Ringden O, Anasetti C, Pavletic S, Casper J, Macmillan ML, Sanders J, Wall D, Kernan NA. Recent decrease in acute graft-versus-host disease in children with leukemia receiving unrelated donor bone marrow transplants. Biol Blood Marrow Transplant. 2009 Mar;15(3):360-6.
Myers KC, Davies SM. Hematopoietic stem cell transplantation for bone marrow failure syndromes in children. Biol Blood Marrow Transplant. 2009 Mar;15(3):279-92. Review.
John P. Perentesis, MD, FAAP Director, Division of Oncology and Cancer Programs 513-636-8241 email@example.com
Director, Division of Oncology and Cancer Programs
Deb Kleisinger Endowed Chair of Novel Cancer Treatments
Director, Leukemia / Lymphoma Program
Cincinnati Children's Principal Investigator, Children’s Oncology Group (COG)
Cincinnati Children's Principal Investigator, National Cancer Institute Pediatric Phase 1 Consortium
Acute myeloid leukemia; neuroblastoma; PNET / Ewing's sarcoma and osteosarcoma; new anticancer drug development; Phase I clinical trials
John P. Perentesis, MD, is a nationally recognized expert in the development of new drugs and molecular therapies for pediatric and young adult cancers and leukemia. His laboratory has developed novel anticancer drugs, and discovered genes important in the growth of normal and malignant cells. His laboratory is also developing the use of tumor and patients genetics research for personalizing therapies. In clinical research, he serves in leadership roles for the National Cancer Institute’s Investigational Drug Steering Committee and the NCI Pediatric Phase I Consortium.
In 2010, Dr. Perentesis was elected by pediatric oncologists from across the country to the national Executive Committee for the NCI-funded Children’s Oncology Group (COG). The COG is the world's largest, cooperative children's cancer research entity. He also is in leadership efforts in the COG for new therapies for leukemia, and adolescent and young adult cancers.
Dr. Perentesis has been elected by his peers for inclusion in Best Doctors in America® from 1998 to 2016.
MD: University of Michigan, Ann Arbor, MI, 1980.
Residency: University of Minnesota Medical School, Minneapolis, MN, 1983.
Fellowship: University of Minnesota Medical School, Minneapolis, MN, 1986.
Postdoctoral: University of Minnesota Medical School, Minneapolis, MN, 1986.
Certification: Pediatrics, 1989; Hematology/Oncology, 1990.
Dorris K, Fouladi M, Davies SM, Perentesis JP, Lawrence JM, Chow LM, Assa'ad A, Uygungil B, Jodele S. . Severe Allergic Reactions to Thiol-based Cytoprotective Agents Mesna and Amifostine in a Child With a Supratentorial Primitive Neuroectodermal Tumor. J Pediatr Hematol Oncol. 2011 Jun 3.
Davies SM, Perentesis JP. Tribute: the American Society of Pediatric Hematology/Oncology (ASPHO), 2011 Distinguished Career Award goes to Dr. William G. Woods. Pediatr Blood Cancer. 2011 Jun;56(6):895-6.
Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley IT, Meshinchi S, Bhatla D, Radloff G, Davies SM. MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010 Aug;55(2):248-53.
Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD Jr, Ingle AM, Blaney SM, Adamson PC. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study. Pediatr Blood Cancer. 2010 Apr;54(4):538-45.
Mehta PA, Gerbing RB, Alonzo TA, Elliott JS, Zamzow TA, Combs M, Stover E, Ross JA, Perentesis JP, Meschinchi S, Lange BJ, Davies SM. FAS promoter polymorphism: outcome of childhood acute myeloid leukemia. A children's oncology group report. Clin Cancer Res. 2008 Dec 1;14(23):7896-9.
Bhatla D, Gerbing RB, Alonzo TA, Conner H, Ross JA, Meshinchi S, Zhai X, Zamzow T, Mehta PA, Geiger H, Perentesis J, Davies SM. Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br J Haematol. 2009 Feb;144(3):388-94.
Geller JI, Wall D, Perentesis J, Blaney SM, Bernstein M; Pediatric Oncology Group study 9376. Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376). Pediatr Blood Cancer. 2009 Mar;52(3):346-50.
Johansson G, Mahller YY, Collins MH, Kim MO, Nobukuni T, Perentesis J, Cripe TP, Lane HA, Kozma SC, Thomas G, Ratner N. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther. 2008 May;7(5):1237-45.
Bhatla D, Gerbing RB, Alonzo TA, Mehta PA, Deal K, Elliott J, Meshinchi S, Geiger H, Perentesis JP, Lange BJ, Davies SM; Children's Oncology Group. DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children's Oncology Group. Leukemia. 2008 Feb;22(2):265-72.
Mo J, Lampkin B, Perentesis J, Poole L, Bao L. Translocation (8;18;16)(p11;q21;p13). A new variant of t(8;16)(p11;p13) in acute monoblastic leukemia: case report and review of the literature. Cancer Genet Cytogenet. 2006 Feb;165(1):75-8. Review.
Russell E. Ware, MD, PhD Marjory J. Johnson Chair of Hematology Translational Research 513-636-4266 firstname.lastname@example.org
Marjory J. Johnson Chair of Hematology Translational Research
Director, Division of Hematology
Associate Director, Global Health Center
Russell Ware, MD, PhD, has been involved with a wide variety of clinical and translational hematology research projects for over 25 years, but his primary interests have focused on sickle cell disease. Dr. Ware has substantial personal experience with directing patient-oriented research, and he currently runs an NIH-funded laboratory effort that investigates genetic modifiers of sickle cell disease. The main focus of his lab research is to understand the phenotypic variability that occurs with hydroxyurea treatment, through the study of hydroxyurea pharmacokinetics, pharmacodynamics, pharmacogenetics, and pharmacogenomics. Dr. Ware is also the national principal investigator for several NIH-funded multicenter sickle cell clinical trials, including the recently completed Stroke With Transfusions Changing to Hydroxyurea (SWiTCH), and the current TCD With Transfusions Changing to Hydroxyurea (TWiTCH) and Sparing Conversion to Abnormal TCD Elevations (SCATE) studies that include non-US clinical sites. Most recently, Dr. Ware has moved his research efforts into the international arena, starting SCD pilot screening programs in Angola, and now conducting clinical trials to determine the safety and efficacy of hydroxyurea in developing countries.
MD: Duke University School of Medicine, Durham, NC, 1979-83.
Residency: Baylor College of Medicine, Houston, TX, 1983-86.
Fellowship: Duke Medical Center, Durham, NC, 1986-89.
PhD: Duke University School of Medicine, Durham, NC, 1987-91.
Certification: Pediatric Hematology/Oncology.
Ndeezi G, Kiyaga C, Hernandez AG, Munube D, Howard TA, Ssewanyana I, Nsungwa J, Kiguli S, Ndugwa CM, Ware RE, Aceng JR. Burden of sickle cell trait and disease in the Uganda Sickle Surveillance Study (US3): a cross-sectional study. Lancet Glob Health. 2016 Mar;4(3):e195-e200.
Aygun B, Mortier NA, Kesler K, Schultz WH, Alvarez O, Rogers Z, Kwiatkowski J, Miller S, Sylvestre P, Cohen A, Ware RE. Therapeutic phlebotomy is safe in children with sickle cell anemia and can be effective treatment for transfusional iron overload. Br J Haematol. 2015;169(2):262-266.
Ware RE, Davis BR, Schultz WH, Brown, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone C, Lee MT, Kwiatkowski JL, Jackson S, Miller ST, Roberts C, Heeney MM, Kalfa TA, Nelson S, Imran H, Nottage K, Alvarez O, Rhodes M, Thompson AA, Rothman JA, Helton KJ, Roberts D, Coleman J, Bonner MJ, Kutlar A, Patel N, Wood J, Piller L, Wei P, Luden J, Mortier NA, Stuber SE, Luban NL, Cohen AR, Pressel, Adams RJ. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2015 Feb;387(10019):661-670.
Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, Jordan L, Lanzkron SM, Lottenberg R, Savage WJ, Tanabe PJ, Ware RE, Murad MH, Goldsmith JC, Ortiz E, Fulwood R, Horton A, John-Sowah J. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014 Sep 10;312(10):1033-48.
Ware RE. Is sickle cell anemia a neglected tropical disease? PLoS Negl Trop Dis. 2013 May 30;7(5):e2120.
Ware RE and Helms RW for the SWiTCH Investigators. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood. 2012;119(17):3925-3932.
Ware RE, Despotovic JM, Mortier NA, Flanagan JM, He J, Smeltzer M, Kimble AC, Aygun B, Wu S, Howard T, Sparreboom A. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood. 2011;118(18):4985-4991.
Wang WC, Ware RE, Miller ST, Iyer RV, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicenter, randomized, controlled trial (BABY HUG). Lancet. 2011;377(9778):1663-1672.
Ware RE, Zimmerman SA, Sylvestre PB, Mortier NA, Davis JS, Treem WR, Schultz WH. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr. 2004;145:346-352.
Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE. Sustained long-term hematological efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103:2039-2045.
Yi Zheng, PhD Director, Experimental Hematology and Cancer Biology 513-636-0595 email@example.com
Director, Experimental Hematology and Cancer Biology
Katherine Stewart Waters Endowed Chair
Co-Director, Cancer and Blood Diseases Institute
Using transgenic and gene targeted mouse models to study the physiological and pathological roles of Rho GTPases and their regulators in hematopoiesis, neurogenesis, lung cancer development and small intestinal stem cell regulations mechanism based, rational design of small molecule inhibitors targeting Rho GTPase signaling modules and pathologic functions in cancer and blood diseases; mouse model studies of mTor signaling function in hematopoietic stem cells and small intestinal stem cells.
Visit the Zheng Lab.
BS: Tsinghua University, Beijing, China, 1986.
MS: Cornell University, Ithaca, NY, 1988.
PhD: Cornell University, Ithaca, NY, 1991.
Postdoctoral Fellow: Cornell University, Ithaca, NY, 1995.
Kesarwani M, Huber E, Kincaid Z, Evelyn CR, Biesiada J, Rance M, Thapa MB, Shah NP, Meller J, Zheng Y, Azam M. Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance. Sci Report. 2015. In press.
Konstantinidis DG, Giger KM, Risinger M, Pushkaran S, Zhou P, Dexheimer P, Yerneni S, Andreassen P, Klingmüller U, Palis J, Zheng Y, Kalfa TA. Cytokinesis failure in RhoA-deficient mouse erythroblasts involves actomyosin and midbody dysregulation and triggers p53 activation. Blood. 2015 Jul 30. [Epub ahead of print]
Barry DM, Xu K, Meadows SM, Zheng Y, Norden PR, Davis GE, Cleaver O. Cdc42 is required for cytoskeletal support of endothelial cell adhesion during blood vessel formation. Development. 2015 Aug 7. [Epub ahead of print]
Yang JQ, Kalim KW, Li Y, Zhang S, Hinge A, Filippi MD, Zheng Y, Guo F. RhoA orchestrates glycolysis for TH2 cell differentiation and allergic airway inflammation. J Allergy Clin Immunol. 2015 Jun 19. [Epub ahead of print]
Lin Y, Zheng Y. Approaches for targeting Rho GTPases in cancer drug discovery. Expert Opin Drug Discov. 2015 Sep;10(9):991-1010.
Zandvakili I, Davis AK, Hu G, Zheng Y. Loss of RhoA exacerbates, rather than dampens, oncogenic K-Ras induced lung adenoma formation in mice. PLoS One. 2015 Jun 1;10(6):e0127923.
Evelyn CR, Biesiada J, Duan X, Tang H, Shang X, Nelson S, Seibel WL, Meller J, Zheng Y. Combined rational design and a high throughput screening platform for identifying chemical inhibitors of a Ras-activating enzyme. J Biol Chem. 2015 May 15;290(20):12879-98.
Mikelis CM, Simaan M, Ando K, Fukuhara S, Sakurai A, Amornphimoltham P, Masedunskas A, Weigert R, Chavakis T, Adams RH, Offermanns S, Mochizuki N, Zheng Y, Gutkind JS. RhoA and ROCK mediate histamine-induced vascular leakage and anaphylactic shock. Nat Commun. 2015 Apr 10;6:6725.
Li J, Zhang L, Chen Z, Xie M, Huang L, Xue J, Liu Y, Liu N, Guo F, Zheng Y, Kong J, Zhang L. Cocaine activates Rac1 to control structural and behavioral plasticity in caudate putamen. Neurobiol Dis. 2015 Mar;75:159-76.
Chang KH, Nayak RC, Roy S, Perumbeti A, Wellendorf AM, Bezold KY, Pirman M, Hill SE, Starnes J, Loberg A, Zhou X, Inagami T, Zheng Y, Malik P, Cancelas JA. Vasculopathy-associated hyperangiotensinemia mobilizes haematopoietic stem cells/progenitors through endothelial AT₂R and cytoskeletal dysregulation. Nat Commun. 2015 Jan 9;6:5914.
Cincinnati Center of Excellence in Molecular Hematology. Principal investigator. National Institutes of Health. Sep 2010–June 2016. NIH P30 DK090971 S2.
Lineage Determination and Tissue Homeostasis in the aged Hematopoietic System. Principal investigator. National Institutes of Health. Aug 2011–July 2016. NIH R01AG040118.
Rho GTPase inhibitors for refrigerated platelet storage. Co-principal investigator. National Institutes of Health. Aug 2014–July 2016. NIH R43HL123103.
Targeting Cdc42 for bone marrow transplant therapies. Principal investigator. National Institutes of Health. April 2015—April 2020. NIH R01CA193350.
Stem cell aging and biomarker studies. Principal investigator. National Institutes of Health. Sep 2015—Aug 2016. NIH R56 AG050650.
Jacob (Jack) J.H. Bleesing, MD, PhD Associate Director, Immunodeficiency and Histiocytosis Program 513-636-4266 HLH@cchmc.org
Associate Director, Immunodeficiency and Histiocytosis Program
Co-Director, Diagnostic Immunology Laboratory
Immunobiology; translational research; immunologic methods development
MD: University of Leiden, Leiden, The Netherlands, 1989.
PhD: University of Leiden, Leiden, The Netherlands, 2002.
Residency: Pediatrics, University of Florida, Gainesville, Florida, 1993.
Fellowship: Allergy/Immunology, Duke University Medical Center, Durham, North Carolina, 1995.
Fellowship: Clinical Laboratory Immunology, National Institutes of Health, Bethesda, Maryland, 2001.
Eckrich MJ, Yang E, Domm J, Ho R, Calder C, Manes B, Bleesing J, Frangoul H. A Unique Clinical Presentation of X-Linked Lymphoproliferative Syndrome With a Novel Mutation in SH2D1A and Review of the Literature. J Pediatr Hematol Oncol. 2010 Oct 21.
Marsh RA, Bleesing JJ, Filipovich AH. Using flow cytometry to screen patients for X-linked lymphoproliferative disease due to SAP deficiency and XIAP deficiency. J Immunol Methods. 2010 Oct 31;362(1-2):1-9.
Marsh RA, Villanueva J, Kim MO, Zhang K, Marmer D, Risma KA, Jordan MB, Bleesing JJ, Filipovich AH. Patients with X-linked lymphoproliferative disease due to BIRC4 mutation have normal invariant natural killer T-cell populations. Clin Immunol. 2009 Jul;132(1):116-23.
Marsh RA, Villanueva J, Zhang K, Snow AL, Su HC, Madden L, Mody R, Kitchen B, Marmer D, Jordan MB, Risma KA, Filipovich AH, Bleesing JJ. A rapid flow cytometric screening test for X-linked lymphoproliferative disease due to XIAP deficiency. Cytometry B Clin Cytom. 2009 Sep;76(5):334-44.
Hansen MD, Filipovich AH, Davies SM, Mehta P, Bleesing J, Jodele S, Hayashi R, Barnes Y, Shenoy S. Allogeneic hematopoietic cell transplantation (HCT) in Hurler's syndrome using a reduced intensity preparative regimen. Bone Marrow Transplant. 2008 Feb;41(4):349-53.
Bhatla D, Davies SM, Shenoy S, Harris RE, Crockett M, Shoultz L, Smolarek T, Bleesing J, Hansen M, Jodele S, Jordan M, Filipovich AH, Mehta PA. Reduced-intensity conditioning is effective and safe for transplantation of patients with Shwachman-Diamond syndrome. Bone Marrow Transplant. 2008 Aug;42(3):159-65.
Zhang K, Johnson JA, Biroschak J, Villanueva J, Lee SM, Bleesing JJ, Risma KA, Wenstrup RJ, Filipovich AH. Familial haemophagocytic lymphohistiocytosis in patients who are heterozygous for the A91V perforin variation is often associated with other genetic defects. Int J Immunogenet. 2007 Aug;34(4):231-3.
JJH Bleesing. Assays for B Cell and Germinal Center Development (unit 7.34). In Current Protocols in Immunology. JE Coligan, BE Bierer, DH Margulies, EM Shevach, W Strober (eds.). Hoboken: John Wiley & Sons, 2004.
JJH Bleesing, TA Fleisher, JM Puck. Autoimmune lymphoproliferative syndrome (ALPS). In Immunologic Disorders in Infants and Children. 5th ed. ER Stiehm, HD Ochs, JA Winkelstein (eds). Philadelphia, PA: WB Saunders, 2004.
Sharat Chandra, MBBS, MD, MRCPCH 513-636-4266 firstname.lastname@example.org
Assistant Professor, UC Department of Pediatrics
Blood and marrow transplant; malignant and primary immune deficiency disorders.
MBBS: Andhra Medical College, University of Health Sciences, Visakhapatnam, India.
Residency: Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India, 1998-2001; University Hospitals of Leicester, South Warwickshire Hospitals NHS, United Kingdom, 2003-2006; University of South Alabama, 2006-2009.
Fellowship: Pediatric Hematology-Oncology, Cincinnati Children’s Hospital Medical Center, 2009-2012.
Certification: MD (Pediatrics), 2001; Royal College of Pediatrics and Child Health (MRCPCH), 2006; Board Certified in General Pediatrics by the American Board of Pediatrics, 2009; Board Certified in Pediatric Hematology-Oncology by the American Board of Pediatrics, 2013.
Pan D, Kalfa TA, Wang D, Risinger M, Crable S, Ottlinger A, Chandra S, Mount DB, Hübner CA, Franco RS, Joiner CH. K-Cl Cotransporter Gene Expression during Human and Murine Erythroid Differentiation. J Biol Chem. 2011 Sep 2; 286(35):30492-503.
Mancao M, Imran H, Chandra S, Estrada B, Figarola M, Sosnowski J, Vidal R. Eastern equine encephalitis virus infection and hemophagocytic lymphohistiocytosis in a 5-month old infant. Pediatr Infect Dis J. 2009 Jun;28(6):543-5.
Chandra S, Haines H, Michie C, Maheshwari A. Developmental Defects in Neutrophils from Preterm Infants. NeoReviews. 2007;8: e368-e376.
Singh M, Mathew JL, Chandra S, Katariya S, Kumar L. Randomized controlled trial of intrapleural streptokinase in empyema thoracis in children. Acta Paediatrica. 2004 Nov; 93(11):1443-5.
Christopher E. Dandoy, MD, MSc 513-636-8424 email@example.com
Hematopoietic stem cell transplantation for children and young adults with malignancy or hemoglobinopathies
Dr. Dandoy is an assistant professor of clinical pediatrics and is a pediatric bone marrow transplant physician in the Department of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Children’s Hospital Medical Center. Dr. Dandoy’s clinical focus is caring for children and young adults requiring hematopoietic stem cell transplantation. Dr. Dandoy’s research focuses are on quality improvement; patient safety; patient and family outcomes; and cardiopulmonary complications, including pulmonary hypertension, after stem cell transplantation.
Dr. Dandoy is the co-chair of the Early Career Council, leader of Quality Improvement-Maintenance of Certification Sponsored Projects, and vice chair of the Certification Subcommittee for the American Society of Pediatric Hematology Oncology.
BS: Weber State University, Ogden, UT, 2003.
MD: University of Utah, Salt Lake City, UT, 2007.
MSc: University of Cincinnati, Cincinnati, OH, 2014.
Residency: Miami Children’s Hospital, Miami, FL, 2010.
Chief Residency: Miami Children’s Hospital, Miami, FL, 2011.
Fellowship: Cincinnati Children's Hospital, Cincinnati Ohio, 2014; Quality Scholar in Healthcare Transformation, James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 2014.
Certification: Pediatrics, 2010; Pediatric Hematology Oncology, 2015.
Best D, Osterkamp E, Demmel K, Kiniyalocts S, Mock S, Mulligan K, Bell A, Doughman C, Flemming M, Flesch L, Hawkins D, Pate A, Bedel A, McKenna LA, Teusink A, Jodele S, Nagarajan R, Perentesis J, Davies SM, Dandoy CE. Increasing Activities of Daily Living is as Easy as 1-2-3. Journal of Pediatric Oncology Nursing. J Pediatr Oncol Nurs. 2015 Dec 31.
Dandoy CE, Hausfeld J, Flesch L, Hawkins D, Demmel K, Best D, Osterkamp E, Bracke T, Nagarajan R, Jodele S, Holt J, Giaccone MJ, Davies SM, Kotagal U, Simmons J. Rapid cycle development of a multi-factorial intervention achieved sustained reductions in central line associated blood stream infections in hematology oncology units at a children's hospital: a time series analysis. BMJ Qual Saf. 2015 Nov 25.
Pate A, Rotz S, Warren M, Hirsch R, Cash R, Myers K, El-Bietar J, Nelson A, Wallace G, Filipovich A, Bleesing J, Chima R, Davies SM, Jodele S, Dandoy CE. Pulmonary hypertension associated with bronchiolitis obliterans after hematopoietic stem cell transplantation. Bone Marrow Transplantation. 2015 Oct 19.
Jodele S, Fukuda T, Mizuno K, Vinks A, Laskin B, Goebel J, Dixon B, Chima R, Hirsch R, Teusink A, Lazear D, Lane A, Myers K, Dandoy CE, Davies SM. Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016 Feb;22(2):307-15.
Dandoy CE, Hariharan S, Weiss B, Demmel K, Timm N, Chiarenzelli J, Dewald MK, Kennebeck S, Langworthy S, Pomales J, et al. Sustained reductions in time to antibiotic delivery in febrile immunocompromised children: results of a quality improvement collaborative. BMJ Qual Saf. 2016 Feb;25(2):100-9.
Dandoy C, Davies SM, Hirsch R, Chima RS, Paff Z, Cash M, Ryan TD, Lane A, El-Bietar J, Myers KC, Jodele S. Abnormal echocardiography seven days after stem cell transplant may be an early indicator of thrombotic microangiopathy. Biology of Blood and Marrow Transplantation. 2015;21(2):379-81.
Dandoy CE, Davies SM, Flesch L, Hayward M, Koons C, Coleman K, Jacobs J, McKenna LA, Olomajeye A, Olson C, Powers J, Shoemaker K, Jodele S, Alessandrini E, Weiss B. A team-based approach to reducing cardiac monitor alarms. Pediatrics. 2014;134(6):e1686-94.
Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J, Myers K, Grimley M, Bleesing J, El-Bietar J, Wallace G, Chima R, Paff Z, Laskin B. Refined diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a prospective study in children and young adults. Blood. 2014;124(4):645-53.
Lerner D, Dandoy C, Hirsch R, Laskin B, Davies SM, Jodele S. Pericardial Effusion in Pediatric SCT Recipients with Thrombotic Microangiopathy. Bone Marrow Transplant. 2014 Jun;49(6):862-3.
Dandoy CE, Hirsch R, Chima R, Davies SM, Jodele S. Pulmonary hypertension after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013 Nov;19(11):1546-56.
Pauline A. Daniels, DO Staff Physician, Bone Marrow Transplantation and Immune Deficiency 513-636-7287 firstname.lastname@example.org
Staff Physician, Bone Marrow Transplantation and Immune Deficiency
DO: Lake Erie College of Osteopathic Medicine, Bradenton, FL.
Residency: Pediatrics, University at Buffalo, Buffalo, NY.
Fellowship: Pediatric Hematology/Oncology, University at Buffalo, Buffalo, NY.
Javier El-Bietar, MD 513-803-2105 email@example.com
Pediatric bone marrow transplantation
Javier El-Bietar, MD, received his medical degree from St. George's University School of Medicine, Grenada, West Indies. He then pursued residency training in general pediatrics at SUNY Downstate in Brooklyn New York where he received an Excellence in Research Award. He continued training in pediatric hematology/oncology at Baylor College of Medicine, Texas Children's Hospital, Houston, TX, where he conducted research exploring the in vitro enhancement of antigen specific cytotoxic T cells used in adoptive immunotherapy. He spent an additional clinical training year with Texas Children's Hospital and the Center for Cell and Gene Therapy following the bone marrow transplant fellowship curriculum. After completion, he joined the faculty of the Division of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Children’s within the UC Department of Pediatrics in 2013. His clinical and research interests include exploring new treatment strategies for post-hematopoietic stem cell transplant-associated co-morbidities.
MD: St. George's University School of Medicine, Grenada, West Indies, 2006.
Residency: Pediatrics, State University of New York, Downstate, Brooklyn, New York, NY.
Fellowship: Pediatric Hematology/Oncology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX.
Board Certification: Pediatrics, 2009; Pediatric Hematology/Oncology, 2013.
El-Bietar JA, Bollard CM. T cell therapies for Epstein-Barr virus-associated lymphomas. Pediatric Hematology and Oncology. 2011 Nov; 28(8):627-39.
Dvorak CC, Bollard CM, El-Bietar J, Filipovich A. Complications of Transplant for Nonmalignant Disorders: Autoimmune Cytopenias, Opportunistic Infections, and PTLD. Educational series. American Society of Bone Marrow Transplant Annual Meeting 2012. Biology and Bone Marrow Transplant. 2012 Jan; 18(1 Suppl):S101-10.
Fallon SC, Redell MS, El-Bietar J, Lopez ME, Vasudevan SA, Brandt ML. Intestinal perforation after treatment of Burkitt’s lymphoma: Case report and review of the literature. Journal of Pediatric Surgery. 2013 Feb; 48(2):436-40.
Michael S. Grimley, MD Member, Langerhans Cell Histiocytosis Center 513-636-5917 firstname.lastname@example.org
Member, Langerhans Cell Histiocytosis Center
Associate Professor, UC Department of Pediatrics
Bone marrow transplantation for primary immunodeficiencies; cord blood transplants; leukemia
MD: Emory University School of Medicine, Atlanta, GA, 1992.
Residency: Wilford Hall Medical Center, Lackland, AFB, TX, 1995.
Fellowship: Cincinnati Children’s Hospital Medical Center, 1999.
Certification: General Pediatrics, Pediatric Hematology/Oncology.
Licenses: Ohio, Texas.
Jubert C, Wall DA, Grimley M, Champagne MA, Duval M. Engraftment of unrelated cord blood after reduced-intensity conditioning regimen in children with refractory neuroblastoma: a feasibility trial. Bone Marrow Transplant. 2011 Feb;46(2):232-7.
Jacobson PA, Huang J, Wu J, Kim M, Logan B, Alousi A, Grimley M, Bolaños-Meade J, Ho V, Levine JE, Weisdorf D. Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant. 2010 Mar;16(3):421-9.
Jacobsohn DA, Gilman AL, Rademaker A, Browning B, Grimley M, Lehmann L, Nemecek ER, Thormann K, Schultz KR, Vogelsang GB. Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study. Blood. 2009 Nov 12;114(20):4354-60.
Pulsipher MA, Wall DA, Grimley M, Goyal RK, Boucher KM, Hankins P, Grupp SA, Bunin N. A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). Br J Haematol. 2009 Dec;147(5):691-9.
Pulsipher MA, Boucher KM, Wall D, Frangoul H, Duval M, Goyal RK, Shaw PJ, Haight AE, Grimley M, Grupp SA, Kletzel M, Kadota R. Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313. Blood. 2009 Aug 13;114(7):1429-36.
Chan KW, McDonald L, Lim D, Grimley MS, Grayson G, Wall DA. Unrelated cord blood transplantation in children with idiopathic severe aplastic anemia. Bone Marrow Transplant. 2008 Nov;42(9):589-95.
Chan KW, Grimley MS, Taylor C, Wall DA. Early identification and management of graft failure after unrelated cord blood transplantation. Bone Marrow Transplant. 2008 Jul;42(1):35-41.
Swinney RM, Wall DA, Thomas PJ, Grimley MS, Taylor C, Tomlinson GE. Familial childhood leukemia cluster with multiple aggressive early-onset hematological malignancies. Leuk Lymphoma. 2006 May;47(5):930-2.
Shaughnessy PJ, Bachier C, Grimley M, Freytes CO, Callander NS, Essell JH, Flomenberg N, Selby G, Lemaistre CF. Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant. 2005 Mar;11(3):188-93.
Parker A, Anderson C, Weiss KL, Grimley M, Sorrells D. Eukaryotic initiation factor 4E staining as a clinical marker in pediatric neuroblastoma. J Pediatr Hematol Oncol. 2004 Aug;26(8):484-7.
Sonata Jodele, MD Clinical Director, Division of Bone Marrow Transplantation & Immune Deficiency 513-636-1565 email@example.com
Clinical Director, Division of Bone Marrow Transplantation & Immune Deficiency
Bone marrow transplantation
MD: Vilnius University School of Medicine, 1988-1994.
Residency: Pediatrics, Downstate HSC at Brooklyn, Brooklyn, NY, 1998-2001.
Fellowship: Pediatric Hematology Oncology, Children's Hospital Los Angeles and Saban Research Institute, Keck School of Medicine University of Southern California, Los Angeles, CA, 2001-2004.
Certifications: Pediatrics, 2001; Pediatric Hematology / Oncology, 2004.
Licenses: California, 2001-present; Ohio, 2004-present.
Jodele S, Zhang K, Zou F, Laskin B, Dandoy CE, Myers KC, Lane A, Meller J, Medvedovic M, Chen J, Davies SM. The genetic fingerprint of susceptibility for transplant associated thrombotic microangiopathy. Blood. 2015 Nov 24.
Jodele S, Fukuda T, Mizuno K, Vinks AA, Laskin BL, Goebel J, Dixon BP, Chima RS, Hirsch R, Teusink A, Lazear D, Lane A, Myers KC, Dandoy CE, Davies SM. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 Feb;22(2):307-15.
Jodele S, Laskin BL, Dandoy CE, Myers KC, El-Bietar J, Davies SM, Goebel J, Dixon BP. A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev. 2015 May;29(3):191-204.
Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J, Myers K, Grimley M, Bleesing J, El-Bietar J, Wallace G, Chima RS, Paff Z, Laskin BL. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a prospective study in children and young adults. Blood. 2014 Jul 24;124(4):645-53.
Jodele S, S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J, Dixon BP, Teusink A, Pluthero FG, Lu L, Licht C, Davies SM. Eculizumab Therapy in Children with Severe Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy. Biol Blood Marrow Transplant. 2014 Apr;20(4):518-25.
Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA, Davies SM, Pluthero FG, Lu L, Laskin BL. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood. 2013 Sep 19;122(12):2003-7.
Chima R, Rodney DC, Mi-Ok K, Li D, Wheeler DS, Davies SM, Jodele S. Improved Outcomes for Stem Cell Transplant Recipients Requiring Pediatric Intensive Care. Pediatric Critical Care Medicine. 2012.
Laskin BL, Goebel J, Davies SM, Jodele S. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplant associated-thrombotic microangiopathy. Blood. 2011 May 19.
Smith AR, Majhail NS, Macmillan ML, Defor TE, Jodele S, Lehmann LE, Krance R, Davies SM. Hematopoietic cell transplantation comorbidity index predicts transplant outcomes in pediatric patients. Blood. 2011 Jan 12.
Laskin BL, Goebel J, Davies SM, Khoury JC, Bleesing JJ, Mehta PA, Filipovich AH, Paff ZN, Lawrence JM, Yin HJ, Pinkard SL, Jodele S. Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplant. 2010 Aug 9.
Naomi E. Joffe, PhD Pediatric Psychologist, Clinical, Behavioral Medicine & Clinical Psychology 513-636-4336 firstname.lastname@example.org
Pediatric Psychologist, Clinical, Behavioral Medicine & Clinical Psychology
CBDI Patient and Family Wellness Center
Pediatric psychology; coping with chronic illness; adherence to treatment/self-management; pain-management; cognitive-behavioral therapy
Naomi Joffe, PhD, joined Behavioral Medicine and Clinical Psychology as an assistant professor of pediatrics within the University of Cincinnati College of Medicine after completing her fellowship at Cincinnati Children’s under the mentorship of Dr. Lori Crosby.
During her fellowship, Dr. Joffe contributed to a study working to improve the transition from pediatric to adult care among young adults with sickle cell disease with the goal of improving patient adherence/self-management and disease outcomes. She continues to collaborate in this area and looks forward to developing quality improvement projects within the Cancer and Blood Diseases Institute (CBDI) to improve psychological care for patients with hematological disorders.
Dr. Joffe also works within the CBDI to help patients diagnosed with hematological disorders cope with the demands of having a chronic illness, improve their adherence to treatment, and learn non-pharmacological strategies to assist in pain management.
PhD: Georgia State University, Atlanta, GA, 2012.
Residency: O’Grady Residency in Behavioral Medicine and Clinical Psychology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2012.
Fellowship: Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2013.
Crosby LE, Joffe NE, Dunseath L, Lee R. Design joins the battle against sickle-cell disease. Design Management Review. 2013.
Joffe NE, Lynch-Jordan AM, Ting TV, Arnold LM, Hashkes PJ, Lovell DJ, Passo MH, Powers SW, Schikler KN, Kashikar-Zuck S. The utility of the PedsQL™ Rheumatology Module as an outcome measure in juvenile fibromyalgia. Arthritis Care and Research. 2013.
Joffe NE, Cohen LL, Masuda Aki. Evaluation of a body pillow to aid pediatric spinal fusion recovery. Children’s Health Care. 2013.
Michael B. Jordan, MD Faculty, Langerhans Cell Histiocytosis Center 513-636-7287 email@example.com
Faculty, Langerhans Cell Histiocytosis Center
Histiocytic disorders: HLH and LCH
MD: UT Southwestern, Dallas, TX, 1993.
Residency: Children's Hospital of Dallas, Dallas, TX, 1996.
Fellowship: The Children's Hospital, Denver, CO, 2002.
Certification: American Board of Pediatrics, 1996; Sub-board of Pediatric Heme/Onc, 2002.
Marsh RA, Vaughn G, Kim MO, Li D, Jodele S, Joshi S, Mehta PA, Davies SM, Jordan MB, Bleesing JJ, Filipovich AH. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 2010 Dec 23;116(26):5824-31.
Marsh RA, Madden L, Kitchen BJ, Mody R, McClimon B, Jordan MB, Bleesing JJ, Zhang K, Filipovich AH. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood. 2010 Aug 19;116(7):1079-82.
Marsh RA, Satake N, Biroschak J, Jacobs T, Johnson J, Jordan MB, Bleesing JJ, Filipovich AH, Zhang K. STX11 mutations and clinical phenotypes of familial hemophagocytic lymphohistiocytosis in North America. Pediatr Blood Cancer. 2010 Jul 15;55(1):134-40.
Lykens JE, Terrell CE, Zoller EE, Divanovic S, Trompette A, Karp CL, Aliberti J, Flick MJ, Jordan MB. Mice with a selective impairment of IFN-gamma signaling in macrophage lineage cells demonstrate the critical role of IFN-gamma-activated macrophages for the control of protozoan parasitic infections in vivo. J Immunol. 2010 Jan 15;184(2):877-85.
Lin AA, Tripathi PK, Sholl A, Jordan MB, Hildeman DA. Gamma interferon signaling in macrophage lineage cells regulates central nervous system inflammation and chemokine production. J Virol. 2009 Sep;83(17):8604-15.
Marsh RA, Villanueva J, Zhang K, Snow AL, Su HC, Madden L, Mody R, Kitchen B, Marmer D, Jordan MB, Risma KA, Filipovich AH, Bleesing JJ. A rapid flow cytometric screening test for X-linked lymphoproliferative disease due to XIAP deficiency. Cytometry B Clin Cytom. 2009 Sep;76(5):334-44.
Jordan MB, Filipovich AH. Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis: a journey of a thousand miles begins with a single (big) step. Bone Marrow Transplant. 2008 Oct;42(7):433-7.
Wojciechowski S, Jordan MB, Zhu Y, White J, Zajac AJ, Hildeman DA. Bim mediates apoptosis of CD127(lo) effector T cells and limits T cell memory. Eur J Immunol. 2006 Jul;36(7):1694-706.
Pooja Khandelwal, MD 513-803-9063 firstname.lastname@example.org